Skip to main content
Equibles

Stephen Dilly

Board Member

Codexis, Inc. (CDXS)

Equibles does not estimate personal net worth.

Get an email with a short summary when Codexis, Inc. publishes a filing, an earnings call transcript or a press release.

Get CDXS alerts

About Stephen Dilly

Stephen Dilly is recorded as Board Member at Codexis, Inc. (CDXS) since January 1, 2020. The newest filing on record that lists Stephen Dilly as Board Member at Codexis, Inc. (CDXS) is dated April 28, 2026. The proxy statement of Codexis, Inc. reports total compensation of $2,194,601 for Stephen Dilly in fiscal 2025, including a base salary of $758,903. Disclosed compensation is on record for 4 fiscal years. Stephen Dilly has spoken on 11 earnings calls across 1 company, most recently for Codexis, Inc. on November 6, 2025. Codexis, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Codexis, Inc. includes Alison Moore (CEO and Board Member), Alison Moore, Ph.D. (CEO and CTO), Dr. Stephen Dilly (CEO) and 7 others.

Stephen Dilly on recent calls

“We've had a very exciting and important few months that have set us up extremely well for the changes we're announcing today. First, we were very pleased to sign the supply assurance agreement with Merck.”
CEO, Codexis, Inc. Q3 FY2025 Earnings Call ·
“Before we begin our comments today, you’ll notice that Chief Operating Officer Kevin Norritt isn't on this call. That's because he's busy at an on-site visit with an important Codexis customer.”
CEO, Codexis, Inc. Q1 FY2025 Earnings Call ·
“I’m very pleased with the progress we’ve made over the last year. Firstly, we’ve worked hard to return our heritage pharma manufacturing business to a healthy growth trajectory.”
CEO, Codexis, Inc. Q4 FY2024 Earnings Call ·
“This has been another strong quarter for Codexis. Let's review a few of the highlights. First, we strengthened our balance sheet by adding $31 million in net proceeds from existing institutional investors via our ATM.”
CEO, Codexis, Inc. Q3 FY2024 Earnings Call ·
“Just a year ago, we announced our strategic priority, focusing on two key areas. Firstly, growing our revenue-generating pharmaceutical manufacturing business, and secondly, enabling the manufacture of siRNA therapeutics through our ECO Synthesis manufacturing platform.”
CEO, Codexis, Inc. Q2 FY2024 Earnings Call ·

Affiliation history

  • Codexis, Inc. (CDXS)

    Board Member

    Proxy statement

    Current

    2020-01-01–present

    Last confirmed April 28, 2026

  • Codexis, Inc. (CDXS)

    CEO

    Proxy statement

    Start not stated–2025-04-24

    Last confirmed by a filing; no departure on record

Company network

Leadership on record at Codexis, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Codexis, Inc. (CDXS) $758,903 $2,194,601
2024 Codexis, Inc. (CDXS) $713,550 $3,472,920
2023 Codexis, Inc. (CDXS) $710,000 $3,122,215
2022 Codexis, Inc. (CDXS) $279,449 $5,893,152

Recent activity